Market Place
Sourcing Support
All News #Library
Biotech
Biofrontera Reports Record 2025 Financial Results & Business
19 Mar 2026 //
GLOBENEWSWIRE
Biofrontera Reports Positive Phase 2B Results For Ameluz
09 Mar 2026 //
GLOBENEWSWIRE
Biofrontera to Report Q4, Full-Year 2025 Results
09 Mar 2026 //
GLOBENEWSWIRE
U.S. Patent Office Invalidates Sun Pharma Patent 11,697,028
26 Feb 2026 //
GLOBENEWSWIRE
Biofrontera Locks Ph1 PK Study of Ameluz for AK
17 Feb 2026 //
GLOBENEWSWIRE
Biofrontera Files Supplemental NDA For Ameluz PDT in Carcinoma
11 Feb 2026 //
GLOBENEWSWIRE
Biofrontera Reports Successful Phase 3 Trial For Ameluz® PDT
09 Feb 2026 //
GLOBENEWSWIRE
Biofrontera Announces Database Locks For Clinical Studies
08 Jan 2026 //
GLOBENEWSWIRE
Biofrontera Completes Ameluz & Rhodoled Transfer FDA Approval
18 Dec 2025 //
GLOBENEWSWIRE
Biofrontera Completes Phase 1 Ameluz Study for Actinic Keratoses
04 Dec 2025 //
GLOBENEWSWIRE
Biofrontera Filed of sNDA for Treatment of sBCC with Ameluz®-PDT
02 Dec 2025 //
GLOBENEWSWIRE
Biofrontera To Release Q3 2025 Financial Results & Host
06 Nov 2025 //
GLOBENEWSWIRE
Biofrontera To Attend Lytham Partners Fall 2025 Investor
26 Sep 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.